Novartis India has reported strong performance during the third quarter ended December 2010 and its net profit has taken quantum jump of 75 per cent to Rs.40.50 crore from Rs.23.15 crore in the corresponding period of last year. Its EBDITA also moved sharply to Rs.60.97 crore from Rs .37.57 crore, a growth of 62.3 per cent. With smart growth in profits, its earnings per share worked out to Rs.12.67 as against Rs.7.24 in the last period.


The company's sales of pharmaceuticals increased by 13.8 per cent to Rs.124.93 crore from Rs.109.81 crore and that of generic up by 21.4 per cent to Rs.11.85 crore from Rs.9.76 crore in the similar period of last year. OTC sales also improved by 13.7 per cent to Rs.28.46 crore from Rs.25.03 crore.


For the nine months ended December 2010, Novartis net sales increased by 13.1 per cent to Rs.537.23 crore from Rs.475.18 crore in the same period of last year. The net profit registered a growth of 27.7 per cent to Rs.112.59 crore from Rs.88.17 crore. Its pharmaceutical sales during the first nine months of 2010-11 increased by 12 per cent to Rs.376.15 crore and generics sales went up by 12.8 per cent to Rs.34.41 crore. OTC sales touched to Rs.74.86 crore as against Rs.62.68 crore, a growth of 19.4 per cent.